| 08:15 - 08:45 |
Light Breakfast
Changing diabetes through early intervention
|
| 09:00 - 09:05 |
Welcome and introduction
Bernhard Ludvik, AT
|
| 09:05 - 09:25 |
Role and success of lifestyle intervention in preventing
diabetes
Jaakko Tuomilehto, FI
|
| 09:25 - 09:45 |
Role and success of pharmacological intervention in
preventing diabetes
Malcolm Nattrass, UK
|
| 09:45 - 10:05 |
UKPDS and the legacy of early glucose control
Rury Holman, UK
|
| 10:05 - 10:25 |
Potential to improve and preserve islet function
Juris Meier, DE
|
| 10:25 - 10:35 |
Panel discussion
|
| 10:35 - 11:00 |
Coffee Break
Impact of GLP-1-based therapy: glycaemic control
and beyond |
| 11:00 - 11:05 |
Welcome and introduction
John Buse, US
|
| 11:05 - 11:25 |
GLP-1 - from discovery to drug development
Michael Nauck, DE
|
| 11:25 - 11:45 |
Glucose control with a GLP-1 analogue
Jiten Vora, UK
|
| 11:45 - 12:05 |
Cardiovascular effects of GLP-1 – added benefits
Michael Davidson, US
|
| 12:05 - 12:25 |
Reaching targets beyond glycaemic control –
a meta-analysis of current and new treatments
Stephen Gough, UK
|
| 12:25 - 12:45 |
A comparison of two GLP-1 therapies
Wolfgang E. Schmidt, DE
|
| 12:45 - 13:00 |
Panel discussion: GLP-1 therapy and its place
in treatment
|
| 13:00 - 14:00 |
Lunch
Striving for glycaemic targets whilst reducing risk |
| 14:00 - 14:10 |
Welcome and introduction
Chantal Mathieu, BE
|
| 14:10 - 14:35 |
ACCORD, ADVANCE, VADT and the UKPDS legacy
Niko Marx, DE
Simon Heller, UK
|
| 14:33 - 15:00 |
Hypoglycaemia and modern insulins
Jens Sandahl Christiansen, DK
|
| 15:00 - 15:15 |
Getting to target: which basal insulin to choose?
Lawrence Blonde, US
|
| 15:15 - 15:35 |
Safety: a primary concern in analogue design
Malcolm Nattrass (UK) and
Peter Kurtzhals (Novo Nordisk, Denmark)
|
| 15:35 - 15:45 |
Achieving glycaemic targets with minimal risk
Chantal Mathieu, BE
|
Symposia Programme
